Progress and contrasts of the development of tivozanib for therapy of kidney cancer

Bibliography

• American Cancer Society. Cancer Facts and Figures 2011. Atlanta GACS; 2011
   Google Scholar
• Margolin KA. Interleukin-2 in the treatment of renal cancer. Semin Oncol 2000;12(2):194-203
   Google Scholar
• Tonini G, Fratto ME, Imperatori M, Predictive factors of response to treatment in patients with metastatic renal cell carcinoma: new evidence. Expert Rev Anticancer Ther 2011;11(6):921-30
   PubMed Web of Science ®Google Scholar
• Letang N, Cabaniols L, Pouessel D, Prognostic factors in renal cell carcinoma. Bull Cancer 2009;96(18):475-84
   PubMed Web of Science ®Google Scholar
• Patil S, Figlin RA, Hutson TE, Prognostic factors for progression-free and overall survival with sunitinib targeted therapy and with cytokine as first-line therapy in patients with metastatic renal cell carcinoma. Ann Oncol 2011;22(2):295-300
   PubMed Web of Science ®Google Scholar
• Kim HL, Seligson D, Liu X, Using tumor markers to predict the survival of patients with metastatic renal cell carcinoma. J Urol 2005;173(5):1496-501
   PubMed Web of Science ®Google Scholar
• Pena C, Lathia C, Shan M, Biomarkers predicting outcome in patients with advanced renal cell carcinoma: Results from sorafenib phase III Treatment Approaches in Renal Cancer Global Evaluation Trial. Clin Cancer Res 2010;16(19):4853-63
   PubMed Web of Science ®Google Scholar
• Thodima VJ, Molina AM, Jia X, Molecular classification of sunitinib response in metastatic renal cell carcinoma (mRCC) patients by gene expression profiling. J Clin Oncol 2011;29(Suppl):abstract 4556
   Web of Science ®Google Scholar
• Nickerson ML, Jaeger E, Shi Y, Improved identification of von Hippel-Lindau gene alterations in clear cell renal tumors. Clin Cancer Res 2008;14(15):4726-34
   PubMed Web of Science ®Google Scholar
• Welsh SJ, Koh MY, Powis G. The hypoxic inducible stress response as a target for cancer drug discovery. Semin Oncol 2006;33(4):486-97
   PubMed Web of Science ®Google Scholar
• Baldewijns MM, van Vlodrop IJ, Vermeulen PB, VHL and HIF signalling in renal cell carcinogenesis. J Pathol 2010;221(2):125-38
   PubMed Web of Science ®Google Scholar
• Maynard MA, Ohh M. Von Hippel-Lindau tumor suppressor protein and hypoxia-inducible factor in kidney cancer. Am J Nephrol 2004;24(1):1-13
   PubMed Web of Science ®Google Scholar
• Rathmell WK, Chen S. VHL inactivation in renal cell carcinoma: implications for diagnosis, prognosis and treatment. Expert Rev Anticancer Ther 2008;8(1):63-73
   PubMed Web of Science ®Google Scholar
• Shibuya M. Structure and function of VEGF/VEGF-receptor system involved in angiogenesis. Cell Struct Funct 2001;26(1):25-35
   PubMed Web of Science ®Google Scholar
• Smith NR, Baker D, James NH, Vascular endothelial growth factor receptors VEGFR-2 and VEGFR-3 are localized primarily to the vasculature in human primary solid cancers. Clin Cancer Res 2010;16(14):3548-61
   PubMed Web of Science ®Google Scholar
• Nakamura K, Taguchi E, Miura T, KRN951, a highly potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, has antitumor activities and affects functional vascular properties. Cancer Res 2006;66(18):9134-42
   PubMed Web of Science ®Google Scholar
• van Kempen LC, Leenders WP. Tumours can adapt to anti-angiogenic therapy depending on the stromal context: lessons from endothelial cell biology. Eur J Cell Biol 2006;85(2):61-8
   PubMed Web of Science ®Google Scholar
• McClelland MR, Carskadon SL, Zhao L, Diversity of the angiogenic phenotype in non-small cell lung cancer. Am J Respir Cell Mol Biol 2007;36(3):343-50
   PubMed Web of Science ®Google Scholar
• Ranieri G, Patruno R, Ruggieri E, Vascular endothelial growth factor (VEGF) as a target of bevacizumab in cancer: from the biology to the clinic. Curr Med Chem 2006;13(16):1845-57
   PubMed Web of Science ®Google Scholar
• Ferrara N. VEGF as a therapeutic target in cancer. Oncology 2005;69(Suppl 3):11-16
   PubMed Web of Science ®Google Scholar
• Teng LS, Jin KT, He KF. Clinical applications of VEGF-trap (aflibercept) in cancer treatment. J Chin Med Assoc 2010;73(9):449-56
   PubMed Web of Science ®Google Scholar
• Kumar R, Crouthamel MC, Rominger DH, Myelosuppression and kinase selectivity of multikinase angiogenesis inhibitors. Br J Cancer 2009;101(10):1717-23
   PubMed Web of Science ®Google Scholar
• Reichardt P. Optimal use of targeted agents for advanced gastrointestinal stromal tumours. Oncology 2010;78(2):130-40
   PubMed Web of Science ®Google Scholar
• Bhargava P, Robinson MO. Development of second-generation VEGFR tyrosine kinase inhibitors: current status. Curr Oncol Rep 2011;13(2):103-11
   PubMed Web of Science ®Google Scholar
• Rixe O, Bukowski RM, Michaelson MD, Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study. Lancet Oncol 2007;8(11):975-84
   PubMed Web of Science ®Google Scholar
• Zhang Y, Guessous F, Kofman A, XL-184, a MET, VEGFR-2 an RET kinase inhibitor for the treatment of thyroid cancer, glioblastoma multiforme and NSCLC. IDrugs 2010;13(2):112-21
   PubMed Web of Science ®Google Scholar
• Tsimafeyeu I, Demidov L, Stepanova E, Overexpression of fibroblast growth factor receptors FGFR1 and FGFR2 in renal cell carcinoma. Scand J Urol Nephrol 2011;45(3):190-5
   PubMed Web of Science ®Google Scholar
• Glen H, Mason S, Patel H, E7080, a multi-targeted tyrosine kinase inhibitor suppresses tumor cell migration and invasion. BMC Cancer 2011;11:309
   PubMed Web of Science ®Google Scholar
• Angevin E, Grunwald V, Lin C, A phase I/II study of TKI258 (dovitinib), a FGFR and VEGFR inhibitor, in patients (pts) with advanced or metastatic renal cell cancer (mRCC): preliminary phase II results [abstract #4203]. ESMO 2010
   Google Scholar
• Tsimafeyeu I, Demido L, Ta H, Fibroblast growth factor pathway in renal cell carcinoma: J Clin Oncol. 2010;28(15 Suppl):abstract 4621
   Google Scholar
• Bellon SF, Kaplan-Lefko P, Yang Y, c-Met inhibitors with novel binding mode show activity against several hereditary papillary renal cell carcinoma-related mutations. J Biol Chem 2008;283(5):2675-83
   PubMed Web of Science ®Google Scholar
• Manning BD. Challenges and opportunities in defining the essential cancer kinome. Sci Signal 2009;2(63):p15
   Web of Science ®Google Scholar
• Eskens F, dJM, Esteves B, Updated results from a Phase I study of AV-951 (KRN951), a potent and selective VEGFR-1, -2 and -3 tyrosine kinase inhibitor, in patients with advanced solid tumors [abstract LB-201]. Proceedings of the 99th Annual Meeting of the AACR; AACR; San Diego, CA; 2008
   Google Scholar
• Rini BI, Cohen DP, Lu DR, Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib. J Natl Cancer Inst 2011;103(9):763-73
   PubMed Web of Science ®Google Scholar
• Fishman MN, Carucci M, Bair AH, Axitinib Pharmacokinetics and blood pressure changes in front-line metastatic Renal Cell Carcinoma (RCC) patients [abstract # 3211]. ESMO; Milan, Italy: 2010
   Google Scholar
• Robinson ES, Khankin EV, Karumanchi SA, Hypertension induced by vascular endothelial growth factor signaling pathway inhibition: mechanisms and potential use as a biomarker. Semin Nephrol 2010;30(6):591-601
   PubMed Web of Science ®Google Scholar
• Rini BI, Escudier B, Tomczak P, Axitinib versus sorafenib as second-line therapy for metastatic renal cell carcinoma (mRCC): results of phase III AXIS trial. 2011 ASCO Annual Meeting; Chicago, Illinois. J Clin Oncol 2011;29(Suppl):abstract 4503
   Google Scholar
• De Luca A, Normanno N. Tivozanib, a pan-VEGFR tyrosine kinase inhibitor for the potential treatment of solid tumors. IDrugs 2010;13(9):636-45; Review. Erratum in: IDrugs 2010;13(10):742
   PubMed Web of Science ®Google Scholar
• Bhargava P, Esteves B, Strahs A, Activity of Tivozanib (AV-951), in patients with different histologic subtypes of renal cell carcinoma (RCC)'. ASCO Genitourinary Cancers Symposium, 2011. J Clin Oncol 2011;29(Suppl 7):abstract 327
   Google Scholar
• Nosov DA, Esteves B, Bhargava P, Final analysis of the phase II randomized discontinuation trial (RDT) of tivozanib (AV-951) versus placebo in patients with renal cell carcinoma (RCC)'. ASCO Annual Meting 2011. J Clin Oncol 2011;29(Suppl):abstract 4550
   Google Scholar
• Bhargava P, Esteves B, Al-Adhami M, Effect of hypertension, nephrectomy, and prior treatment on the efficacy of tivozanib (AV-951) in a phase II randomized discontinuation trial (RDT) in patients with renal cell carcinoma (RCC) [abstract no. 342]. 2010 Genitourinary Cancers Symposium; 2010
   Google Scholar
• Motzer RJ, Escudier B, Oudard S, Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 2008;372(9637):449-56
   PubMed Web of Science ®Google Scholar
• Hutson T, Escudier B. Alternating VEGF and mTOR pathways. 5th European International Kidney Cancer Symposium; 7 May 2010; Warsaw, Poland
   Google Scholar
• Mulders P. Vascular endothelial growth factor and mTOR pathways in renal cell carcinoma: differences and synergies of two targeted mechanisms. BJU Int 2009;104(11):1585-9
   PubMed Web of Science ®Google Scholar
• Patnaik A, Ricart A, Cooper J, A phase I, pharmacokinetic and pharmacodynamic study of sorafenib (S), a multi-targeted kinase inhibitor in combination with temsirolimus (T), an mTOR inhibitor in patients with advanced solid malignancies. 2007 ASCO Annual Meeting Proceedings Part I. Volume 25 J Clin Oncol 2007;18(Suppl):3512
   Google Scholar
• Bukowski RM, Kabbinavar FF, Figlin RA, Randomized phase II study of erlotinib combined with bevacizumab compared with bevacizumab alone in metastatic renal cell cancer. J Clin Oncol 2007;25(29):4536-41
   PubMed Web of Science ®Google Scholar
• Feldman DR, Baum MS, Ginsberg MS, Phase I trial of bevacizumab plus escalated doses of sunitinib in patients with metastatic renal cell carcinoma. J Clin Oncol 2009;27(9):1432-9
   PubMed Web of Science ®Google Scholar
• Fischer P, Carducci MA, Phase I study combining treatment with temsirolimus and sunitinib malate in patients with advanced renal cell carcinoma. J Clin Oncol 2008;26(20 Suppl):abstract 16020
   Web of Science ®Google Scholar
• Negrier S, Gravis G, Perol D, Temsirolimus and bevacizumab, or sunitinib, or interferon alfa and bevacizumab for patients with advanced renal cell carcinoma (TORAVA): a randomised phase 2 trial. Lancet Oncol 2011;12(7):673-80
   PubMed Web of Science ®Google Scholar
• Kabbinavar FF, Srinivas S, Hauke RJ, Results from a phase I trial of tivozanib (AV-951) combined with temsirolimus therapy in patients (pts) with renal cell carcinoma (RCC). J Clin Oncol 2011;29(Suppl):abstract 4549
   Google Scholar
• Available from: http://clinicaltrials.gov [Accessed 23 October 2011]
   Google Scholar
• Mayer EL, Scheulen ME, Beckman J, Combination of tivozanib (AV-951) with weekly paclitaxel for metastatic breast cancer: results of a phase I study. J Clin Oncol 2011;29(Suppl):abstract 1092
   Web of Science ®Google Scholar
• Eskens F, Oldenhuis CN, Bhargava P, A phase Ib, open-label, dose-escalation study of tivozanib and FOLFOX6 in patients (pts) with advanced gastrointestinal (GI) tumors. J Clin Oncol 2011;29(Suppl 4):abstract 549
   Web of Science ®Google Scholar
• Rugo HS, Herbst RS, Liu G, Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: pharmacokinetic and clinical results. J Clin Oncol 2005;23(24):5474-83
   PubMed Web of Science ®Google Scholar
• Campas C, Bolos J, Castaner R. Tivozanib. Drugs Future 2009;34(10):793
   Web of Science ®Google Scholar